Phosphatidylinositol-3-Kinase Gamma (PI-3-Ky)
Phosphatidylinositol 3-kinase p110gamma (PI3Kgamma), the only member of the PI3K-family of kinases known to be linked to G protein-coupled receptors, has gained increasing attention as a promising drug target for the treatment of inflammatory disease.
Extensive target-validation data are available, which are derived from studies using both pharmacological and genetic tools. More recent findings have uncovered further therapeutic applications for PI3Kgamma inhibitors, opening up potentially huge opportunities for these drugs (1).
Max Planck Society through its licensing agency Max Planck Innovation GmbH invites interested licensees pursuing work related to and utilizing Phosphatidylinositol 3 -kinase p110 gamma (PI3Kgamma) to consider to join the already existing pool of licensees by obtaining a non-exclusive license for the broad intellectual property rights on Phosphatidylinositol 3-kinase p110gamma (PI3Kgamma), e.g. in the fields of drug development and/or diagnostics and/or production and/or research.
US issued patent US 5,885,777 Mar 23, 1999
EP issued patent EP 0786004 Aug 08, 2001 valid in AT,CH,DE,DK,FR,GB
JP issued patent JP 3949162 July 25, 2007
CA patent pending